Alpha-GPC vs. Citicoline: Which Choline Source Is Best for Brain Health?
Both alpha-GPC and citicoline deliver choline to the brain, but they differ in safety, mechanism, and evidence base. We compare what the research actually shows — including a major stroke risk signal for alpha-GPC — so you can make an informed choice.
Choline is an essential nutrient your brain uses to build cell membranes, produce the neurotransmitter acetylcholine, and support DNA repair through methylation. Every neuron in your brain depends on a steady choline supply to function. It's foundational infrastructure, not an optional input.
Most people don't get enough. The adequate intake is 550 mg/day for men and 425 mg/day for women. In the U.S., only about 6.6% of adults meet that target (Wallace & Fulgoni 2016, based on NHANES 2009–2012 data). Canadian data from Health Canada's 2015 community health survey tells a similar story: mean choline intake falls below the adequate intake across every age group. Dietary sources like egg yolks, liver, and beef help, but consistently hitting the target through food alone is difficult for most people.
Closing that gap matters for baseline brain health. But the more interesting question, and likely the reason you're here, is how citicoline vs alpha-GPC actually compare when the goal goes beyond correcting a deficiency to actively enhancing cognitive performance. That's where the conversation shifts from nutrition to nootropics.
Two compounds dominate that conversation: alpha-GPC and citicoline (CDP-choline). Both deliver choline to the brain, but that's roughly where the similarity ends. They have different mechanisms of action, different secondary effects, and meaningfully different bodies of clinical evidence. Alpha-GPC delivers a concentrated dose of choline efficiently. Citicoline delivers choline alongside cytidine, a precursor to uridine, which feeds a separate pathway involved in synaptic membrane synthesis. That distinction changes the comparison entirely.
Most online comparisons pick a winner based on a single number: choline yield per gram, price per serving, or one cherry-picked study. This article does something different. It covers what each compound actually does once absorbed, compares them head-to-head across the outcomes people care about (memory, focus, neuroprotection, acute performance), addresses the cardiovascular safety question that most articles skip, and gives you practical dosage and timing guidance so you can make an informed decision based on your goals. It ends with a decision table that maps your specific goal to the best-supported compound, dose, and timing — so if you'd rather skip to that, you can.
NeuroVesa sells eudopa™, a brain health supplement containing citicoline as one of its main ingredients. This article evaluates both compounds against the clinical evidence. Where the evidence favors alpha-GPC, we say so. We believe the analysis is objective, but we want to disclose the potential conflict of interest and let you judge for yourself.
This article goes deep on the science. If you already know the basics and want the bottom line, skip to the practical guide — it has a decision table mapping your goal to the best option, dose, and timing.
Alpha-GPC: What It Is and How It Works
Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a choline compound found naturally in your brain, where it exists as a component of cell membrane phospholipids. It's also present in small amounts in foods like eggs, dairy, and organ meats, though not at levels that are meaningful for supplementation. As a supplement, alpha-GPC is typically manufactured through enzymatic processing of soy or sunflower lecithin.
Structurally, alpha-GPC's defining feature is its choline density. It is roughly 40% choline by weight, more than any other commonly available choline supplement. That means per milligram, you're getting more raw choline than you would from choline bitartrate, phosphatidylcholine, or other forms. If your primary goal is maximizing choline delivery to the brain, alpha-GPC is purpose-built for that.
How Alpha-GPC Works in the Brain
Alpha-GPC is absorbed in the small intestine and enters the bloodstream. Once it reaches the brain, enzymes cleave it into two components: free choline and glycerophosphate. The choline is used primarily to synthesize acetylcholine, the neurotransmitter involved in memory formation, attention, and learning. The glycerophosphate fragment contributes modestly to membrane phospholipid synthesis, though this is a secondary effect rather than a primary mechanism.
In short, alpha-GPC is the most concentrated choline supplement available, at roughly 40% choline by weight. Its primary role is feeding acetylcholine synthesis, with a modest secondary contribution to membrane phospholipids via glycerophosphate. If your goal is to maximize the amount of choline reaching your brain per capsule, alpha-GPC is the most efficient tool for that job.
Citicoline: What It Is and How It Works
Citicoline (also called CDP-choline) is a naturally occurring compound found in every cell in your body, where it serves as an intermediate in the synthesis of phosphatidylcholine, the most abundant phospholipid in cell membranes. As a supplement, citicoline is commercially available in two forms: a sodium salt (used in pharmaceutical formulations in some countries) and a free base inner salt, which is the form sold as a dietary supplement. Cognizin, produced by Kyowa Hakko through a fermentation process, is a widely available branded version of the free base form.
What makes citicoline distinct among choline supplements is that it delivers two brain nutrients in one molecule, not just one. It is roughly 18% choline by weight, less than half of alpha-GPC's concentration. But when your body breaks it down, it splits into two components: choline and cytidine. Your body then converts that cytidine into uridine, a nucleoside your brain uses to produce phospholipids for cell membranes, including the synaptic membranes that neurons depend on to form and maintain connections. That second component is what makes citicoline a fundamentally different kind of supplement.
How Citicoline Works in the Brain
The choline half of citicoline works the same way choline from any source does: it feeds acetylcholine synthesis and contributes to cell membrane maintenance. Where citicoline diverges is the uridine side. Your body converts the cytidine from citicoline into uridine, a building block your brain uses to produce the phospholipids that make up cell membranes, including the synaptic membranes that neurons depend on to communicate. A standard 500 mg dose raises circulating uridine levels by as much as 70 to 90% for five to six hours (Wurtman et al. 2000). No common food has been shown to meaningfully raise uridine levels in adults, which is why citicoline is considered one of the only practical ways to increase this substrate.
At a biochemical level, your brain converts that uridine into UTP, then CTP, which feeds the Kennedy pathway, the primary route for manufacturing the phospholipid membranes that neurons depend on. The key enzyme in this pathway normally runs below its full capacity because the brain doesn't produce enough CTP to keep it fully active (based on preclinical measurements). Citicoline addresses both sides of the bottleneck at once: uridine conversion increases CTP supply, while choline provides the pathway's other essential input. The result is increased phospholipid production, the structural material neurons use to build and maintain synaptic connections.
Whether this translates to measurable new synapse formation in humans hasn't been directly confirmed. In animal models, supplying these substrates increased the number of synaptic connections and elevated synaptic proteins in the hippocampus, and the pharmacokinetic data confirms the substrates reach circulation in humans. But direct human confirmation of synaptogenesis at supplemental doses remains a gap in the literature.
The core distinction is this: citicoline delivers both choline and uridine, a membrane-building substrate that can't be meaningfully obtained from food. This gives it access to a structural brain maintenance pathway that other choline supplements don't reach. The lab evidence for this pathway is strong; direct human confirmation at supplemental doses is still an open question. With both compounds' mechanisms now on the table, the next question is what actually happens after you swallow each one.
Citicoline gives your brain two things at once: choline (which alpha-GPC also provides) and uridine (which it doesn't). Your brain uses both of these together to build the membranes that neurons need to form connections. Think of it as delivering both the bricks and the mortar, rather than just the bricks. The science on this pathway is strong in lab settings. The remaining question is exactly how much membrane-building happens at the doses people actually take.
Absorption, Timing, and Delivery: How Alpha-GPC and Citicoline Behave in Your Body
This section gets into the science of how these compounds are absorbed, how fast they work, and what your body actually receives at different doses. It's more technical than the sections above. If you'd rather skip to the practical comparison of outcomes, you can jump ahead to the head-to-head results.
The short version: citicoline's absorption is one of the best-characterized of any supplement, with dose-response data spanning four decades. Alpha-GPC's oral absorption data rests on a single study at a single dose, with high variability between individuals. That gap in evidence depth doesn't mean alpha-GPC is ineffective, but it shapes how confidently we can interpret the clinical trial results that follow.
Read the full pharmacokinetic analysis
The previous sections covered what alpha-GPC and citicoline are. This section asks a different question: how well do we actually understand what happens when you swallow each one? Both are absorbed in the gut, but the depth of evidence behind each is surprisingly lopsided.
Alpha-GPC vs Citicoline: Absorption and Bioavailability
Both alpha-GPC and citicoline are water-soluble compounds absorbed in the small intestine after oral dosing. Beyond that shared starting point, the evidence diverges sharply.
Citicoline's oral absorption is well-characterized. A radiolabeled study (Dinsdale et al. 1983) found less than 1% of an oral dose recovered in feces over five days, indicating virtually complete absorption.
Oral bioavailability approaches 100%. Multiple reviews (Secades 2006, Grieb 2014) confirm that oral citicoline produces plasma profiles comparable to intravenous administration, making it one of the few supplements where this claim holds up under scrutiny.
The metabolic pathway is well-mapped. After absorption, citicoline undergoes rapid hydrolysis, releasing choline and cytidine (which converts to uridine in humans). This pathway is consistent across studies spanning four decades.
Alpha-GPC's oral absorption is less well understood. The compound is absorbed in the small intestine, but recent research (Chen et al. 2024) identified a specific intestinal enzyme, Gpcpd1, that cleaves alpha-GPC into free choline and glycerophosphate before absorption.
Intact alpha-GPC has never been detected in human blood after oral dosing. All human PK studies measure free choline as the analyte, not the parent molecule. What reaches your bloodstream after swallowing alpha-GPC is its hydrolysis products, not alpha-GPC itself.
This matters because a significant portion of alpha-GPC's clinical literature used injection, not oral dosing. With injection, the intact molecule enters circulation directly. With oral dosing, it doesn't. The full implications of that asymmetry are covered in the "How Strong Is the Evidence?" section.
How Fast Do Alpha-GPC and Citicoline Work?
In plain terms: Alpha-GPC appears to peak in the blood around 3.5–4 hours after a dose, but with huge individual variation. Citicoline shows a two-phase pattern: a first peak around 1–2 hours, then a second, broader elevation around 24 hours as choline is recycled from tissues.
Alpha-GPC's timing data comes from a single study. Min et al. 2019 gave 48 healthy Korean men a single 1,200 mg oral dose. Plasma choline peaked at approximately 3.5 to 4 hours post-dose, with an elimination half-life of roughly 5 to 7 hours.
The variability between individuals was high. Standard deviations on both peak time and half-life were large (Tmax: 3.85 ± 3.19 hours), meaning some subjects likely peaked much earlier or later than the mean.
That single study is the entire oral PK dataset for alpha-GPC in humans. One dose, one population, 12 hours of blood sampling. No dose-response data, no food-effect data, no multiple-dose steady-state characterization. For a compound sold globally as both a supplement and a prescription drug, this is a remarkably thin pharmacokinetic evidence base.
Citicoline's time-course is better defined and more complex. Wurtman et al. 2000 tested three doses (500, 2,000, and 4,000 mg) in 12 healthy subjects and tracked plasma levels over 12 hours.
Citicoline produces a biphasic choline curve. A first peak appears at approximately 1 to 2 hours post-dose, followed by a second, broader peak at approximately 24 hours (documented across Dinsdale 1983, Grieb 2014, and Sarkar 2012). The second peak likely reflects re-release of choline from tissue phospholipid pools rather than a second wave of absorption.
Uridine elevation is substantial and sustained. A 500 mg dose raised circulating uridine levels by 70 to 90% above baseline for five to six hours. Cytidine itself was not reliably detectable in plasma at any dose, confirming that in humans, citicoline's cytidine component is rapidly and completely converted to uridine, the circulating form that reaches the brain.
What Alpha-GPC and Citicoline Actually Deliver
The simplest pharmacological comparison is what your body actually receives when you take each compound.
Alpha-GPC is roughly 40% choline by weight. A 600 mg dose delivers approximately 240 mg of choline plus glycerophosphate, which contributes modestly to membrane phospholipids. At the molecular level, the choline delivered is indistinguishable from choline released by any other source. Its value is concentration and efficiency of delivery.
Citicoline is roughly 18% choline by weight. A 500 mg dose delivers approximately 90 mg of choline plus cytidine, which your body converts entirely to uridine. That uridine elevation persists for five to six hours per dose and feeds the Kennedy pathway as described in the Citicoline section above.
The trade-off is straightforward: alpha-GPC delivers more choline per milligram, citicoline delivers less choline but adds a second active component that alpha-GPC does not provide. Whether that second component matters more than the extra choline depends on the outcome you are optimizing for, which is what the following sections address.
Dose-Response: Does More Alpha-GPC or Citicoline Mean Better Results?
For alpha-GPC, no dose-response pharmacokinetic data exists in humans. Min et al. 2019 tested only 1,200 mg. Whether 300 mg or 600 mg (the more common supplement doses) produce proportionally lower plasma choline peaks, or whether the relationship is non-linear, is unknown.
Citicoline has dose-response data across a meaningful range. Wurtman et al. 2000 tested 500, 2,000, and 4,000 mg. Choline elevation remained dose-dependent across all three doses. Uridine elevation plateaued between 2,000 and 4,000 mg.
That plateau has a practical implication. It suggests saturation of the cytidine-to-uridine conversion pathway at higher doses: doubling the dose beyond a certain point increases choline delivery but does not proportionally increase uridine delivery. At the standard 500 mg dose, both pathways appear to be operating well below saturation.
PK Profile Cards
These cards synthesize the available pharmacokinetic data for each compound. Toggle between them to compare.
The contrast in those profiles is worth sitting with for a moment. Citicoline's pharmacokinetics are backed by four decades of data across multiple doses and populations. Alpha-GPC's oral profile rests on a single study. That asymmetry doesn't tell us that alpha-GPC is ineffective, but it does affect how confidently we can interpret the clinical trial results that follow. With that context in place, the next section turns to the question most readers came here to answer: when these two compounds are tested against actual cognitive and physical outcomes, which one performs better?
Alpha-GPC vs Citicoline: Head-to-Head on the Outcomes That Matter
Alpha-GPC vs Citicoline for Memory and Cognition
Memory, learning, and overall cognitive function are the outcomes with the most clinical data for both compounds, and the area where the difference in evidence quality is most pronounced.
Citicoline's evidence in healthy adults is the broadest for either compound. The strongest single trial is Nakazaki et al. 2021: 100 healthy adults aged 50 to 85 received 500 mg of citicoline (as Cognizin) or placebo daily for 12 weeks. The citicoline group showed significant improvement on a composite episodic memory endpoint combining word list and narrative recall.
The study design was rigorous. Double-blind, placebo-controlled, with 99% compliance and pre-registered outcomes. It is industry-funded by Kyowa Hakko (the manufacturer of Cognizin), which should be noted, though the design itself holds up to scrutiny.
One important nuance on the primary endpoint. The composite score technically missed significance after multiple comparison correction. The secondary memory outcomes were robust. Whether you read this as "the trial was positive" or "the trial narrowly missed its primary endpoint" depends on how strictly you interpret multiple comparison corrections. Both readings are defensible.
That trial sits within a broader pattern. Al-Kuraishy and Al-Gareeb (2020) found improved working memory in healthy young adults over two weeks. McGlade et al. (2012) demonstrated attentional benefits at 250 mg per day in healthy women aged 40 to 60. McGlade et al. (2019) found improved attention and motor speed in healthy adolescent males.
Across these trials, citicoline has been tested in healthy people spanning ages 13 to 85, in both sexes. No single trial is definitive on its own, but the pattern across multiple independent trials and populations is the strongest evidence either compound has in this space.
Citicoline was tested against a placebo in 100 older adults for 12 weeks. The people taking citicoline got better at remembering words and stories. The main "scorecard" the researchers set up beforehand just barely missed the statistical finish line, but all the individual memory tests pointed in the same direction. Think of it like a student who scored 89.5 when the pass mark is 90: the overall performance was strong, but the technicality matters to scientists. Multiple other trials in different age groups have found similar memory benefits, which makes the overall picture more convincing than any single study alone.
Alpha-GPC's oral evidence for memory is newer but positive. Jeon et al. 2024 randomized 100 patients with amnestic mild cognitive impairment to 600 mg/day of oral alpha-GPC or placebo for 12 weeks. The alpha-GPC group showed significant improvement on the ADAS-cog, a standard cognitive assessment, including on delayed recall. This is a well-designed, multicenter, double-blind trial, and the strongest piece of oral evidence alpha-GPC has for memory.
The key limitation is population. MCI patients are not the same as healthy adults. A compound that improves cognition in people with measurable decline may or may not do the same in people whose cognition is intact.
This trial answers one question but not another. "Does oral alpha-GPC help people who are already losing cognitive function?" receives a provisional yes. "Does oral alpha-GPC enhance memory in healthy people?" has no oral evidence yet.
Alpha-GPC was tested in 100 people who were already experiencing early memory problems ("mild cognitive impairment"). After 12 weeks, the group taking alpha-GPC scored better on standard memory tests than the placebo group. That's a promising result, but there's an important catch: we don't yet know if alpha-GPC would have the same effect in someone whose memory is working normally. Helping a struggling brain recover is not the same as boosting one that's already healthy. This is currently the only oral alpha-GPC memory trial, so it needs to be replicated before drawing firm conclusions.
Behind the oral data sits a substantial body of injection-based research. This includes a meta-analysis and a multi-year combination therapy trial series. That evidence is real and generally positive, but it comes from a different route of administration and, in the case of the combination trials, cannot isolate alpha-GPC's independent contribution. The full assessment is covered in the "How Strong Is the Evidence?" section.
Citicoline is the stronger pick for memory, and it's not especially close. The evidence base is broader, tested in healthy people, and replicated across multiple independent trials. If you're a healthy adult looking to support memory long-term, this is the better-backed option right now.
Alpha-GPC's only oral memory trial was in people with existing cognitive decline, a different population with different biology. That result is promising on its own terms, but it doesn't tell you much about what alpha-GPC will do for a healthy brain. If you or someone you know is dealing with early cognitive decline, it's worth flagging to a doctor. Otherwise, it's not the compound with the data behind it for this use case.
Neither compound has a long-term memory trial lasting a year or more, so we're still working with relatively short windows. That's a gap across the entire category, not a knock on either one specifically.
Alpha-GPC vs Citicoline for Focus and Processing Speed
Focus, reaction time, and processing speed are the outcomes most associated with the nootropic appeal of choline supplements. This is also where the two compounds offer genuinely different temporal profiles, with different implications for how you'd use each one.
Alpha-GPC has the only controlled evidence for acute, same-day effects. Kerksick 2024 gave healthy young men single doses of alpha-GPC at 315 mg and 630 mg, then tested cognitive performance 60 minutes later.
The alpha-GPC group showed significant improvement on the Stroop test, a standard measure of attention and cognitive flexibility, at both doses. The high dose also produced significantly faster completion time. Neither dose affected performance on the N-Back (working memory) or Flanker (response inhibition) tasks.
This is a narrow but real finding. The Stroop test specifically measures the ability to suppress an automatic response in favor of a controlled one, which maps onto what people colloquially mean by "focus." The null results on N-Back and Flanker suggest the effect may be specific to attentional control rather than a broad cognitive enhancement. One trial in 20 young men is not sufficient to draw firm conclusions, but it is the only placebo-controlled evidence showing a cognitive effect within an hour of a single dose for either compound.
In one study, men who took a single dose of alpha-GPC performed measurably better on a task that requires ignoring distractions and staying focused, and this happened within an hour. However, it didn't improve their working memory or ability to filter out conflicting information on other tests. So the effect seems specific to one type of focus rather than a general brain boost. It's a real finding, but from just 20 people in one study, so it's too early to treat it as settled science.
Citicoline's attention benefits build over weeks of daily use. Al-Kuraishy and Al-Gareeb (2020) found improved reaction time and vigilance in healthy young adults after two weeks. McGlade et al. (2012) demonstrated fewer omission and commission errors on a sustained attention task in healthy women aged 40 to 60 after 28 days at 250 mg per day.
McGlade et al. (2019) extended this to adolescent males. After 28 days of citicoline, subjects showed improved psychomotor speed and reduced impulsivity, with higher weight-adjusted doses showing better accuracy and signal detectability. Bruce et al. (2014) reported improved sustained concentration with a citicoline-caffeine combination, though the caffeine confound limits what can be attributed to citicoline alone.
The pattern across these studies is consistent. Daily citicoline produces measurable attentional improvement over a period of two to four weeks, across different populations and age groups. No single trial is large or long enough to be definitive, but the convergence across multiple independent studies strengthens the overall signal.
Citicoline also has acute single-dose data, though it tells a more nuanced story. The University of Ottawa group (Knott et al. 2014, 2015) conducted three crossover studies giving healthy men single doses of 500 mg or 1,000 mg of CDP-choline and measuring effects within hours.
The results were consistently baseline-dependent. Citicoline improved cognition and EEG markers in low baseline performers, had no effect in medium performers, and showed possible detriment in high performers. This is a meaningfully different profile than alpha-GPC's Kerksick finding, which showed improvement across the full sample without baseline stratification.
Whether the difference reflects a real mechanistic distinction or simply different analytical approaches is unclear. Knott stratified by baseline; Kerksick did not. The available data cannot distinguish between these explanations.
When citicoline was tested as a single dose (rather than taken daily), the results depended heavily on where someone started. People who already had sharp focus didn't benefit, and may have done slightly worse. People who started with below-average focus saw the most improvement. This is a different pattern from alpha-GPC, which seemed to help everyone in its study equally. The practical takeaway: if you feel like your focus is already strong, a single dose of citicoline may not give you a noticeable boost. If you feel like you're running below your best, the data suggests citicoline may help more.
Alpha-GPC is like espresso: evidence of a measurable effect within the hour, from a single serving. Citicoline is like a fitness routine: the benefits build over weeks of daily consistency. Both approaches have value, but they serve different timing needs.
This is the one category where the answer depends entirely on what you're looking for. If you want a noticeable effect from a single dose, alpha-GPC has the only evidence of that for either compound. If you want steady improvement over weeks of daily use, citicoline has more data across more populations.
The catch is that neither evidence base is large. Alpha-GPC's acute signal comes from one small study. Citicoline's daily-use data comes from several small studies that all point the same direction, which is more convincing but still not settled. If your focus feels consistently below where it should be, citicoline's daily approach has the more relevant data. If you want something for occasional high-demand days, alpha-GPC is the only option with controlled evidence behind it.
Which Supplement Protects the Brain Long-Term?
Neuroprotection refers to whether a compound can slow or prevent the structural and functional brain changes that drive age-related cognitive decline: synaptic loss, membrane degradation, neuroinflammation, and ultimately, conversion from normal cognition to mild impairment or dementia. This section evaluates each compound's evidence for those long-term outcomes specifically, not the short-term performance gains covered above.
Citicoline's neuroprotective case rests on multiple converging lines of evidence, none of which is individually conclusive. The foundation is the uridine pathway described in the Citicoline section above. Citicoline supplies the rate-limiting substrate (uridine, via cytidine conversion) for the Kennedy pathway alongside choline, the pathway's other key input. The output is increased phospholipid production for synaptic membranes.
Alpha-GPC does not deliver uridine. This gives citicoline a mechanistic advantage for structural brain maintenance that stands independent of any choline-related benefit. Whether this mechanistic advantage translates to measurable neuroprotection in humans over years is the question the evidence can only partially answer.
Citicoline also appears to influence neurotransmitter systems beyond acetylcholine. The Secades 2006 pharmacological review documented effects on dopamine and norepinephrine activity in the central nervous system, mediated through citicoline's effects on membrane phospholipid composition. Wang et al. (2005) found that uridine increased potassium-evoked dopamine release by 20% in aged rats.
Human imaging and behavioral data are consistent with this multi-neurotransmitter profile. Killgore et al. (2010) found altered activation in dopamine-rich brain regions on fMRI after citicoline supplementation, and Renshaw et al. (1999) reported reduced cocaine craving in dependent subjects, a finding consistent with dopaminergic restoration. These signals are mechanistically coherent, but no study has directly measured brain dopamine levels in healthy humans after citicoline supplementation. The evidence supports a multi-neurotransmitter profile, but "dopamine boost" would overstate the certainty.
On the clinical side, citicoline has a long track record in stroke rehabilitation research. A 2025 network meta-analysis by Zhao et al. found that citicoline at multiple dose levels improved neurological function and reduced mortality in acute ischemic stroke across 13 studies. However, this positive signal is largely driven by smaller, older trials. The largest acute stroke trial, ICTUS (2,298 patients), was negative: citicoline did not prevent stroke damage in the acute setting. The positive evidence is specifically in post-stroke cognitive rehabilitation and longer-term recovery.
A separate finding adds to the neuroprotective picture. Al-Kuraishy and Al-Gareeb (2020) found that citicoline reduced malondialdehyde (MDA), a marker of oxidative stress, in healthy young adults over two weeks. Oxidative damage is a primary driver of age-related neurodegeneration, so a compound that reduces oxidative stress markers while supporting membrane repair has a coherent neuroprotective story, though this is a single biomarker finding in a short trial.
Citicoline's neuroprotection story works on two levels. First, it provides building materials your brain needs to repair and maintain the membranes that wrap every nerve cell. Think of it like giving your body extra supplies for ongoing house maintenance. Alpha-GPC doesn't supply these same materials. Second, citicoline appears to support not just acetylcholine (the "memory chemical") but also dopamine and norepinephrine, chemicals involved in motivation, mood, and alertness. Brain scans and behavioral studies in humans are consistent with this, though no one has directly measured dopamine levels in a healthy person's brain after taking citicoline. The evidence is pointing in a promising direction, but it's not yet definitive.
Alpha-GPC's neuroprotection evidence is observational but large-scale. The most significant study is Kim et al. 2025, which tracked over 508,000 patients with mild cognitive impairment using the South Korean national health insurance database. Alpha-GPC users showed 10% lower Alzheimer's conversion risk and 17% lower vascular dementia conversion risk compared to non-users. Both findings held after statistical adjustment.
The scale is impressive, but the design imposes hard limits on interpretation. The study is observational, not randomized. Confounding by indication is a real concern: patients prescribed alpha-GPC may have differed systematically from those who were not. And it tracked prescription alpha-GPC in a South Korean clinical population, not over-the-counter supplement use.
The ASCOMALVA trial series adds a second line of evidence. Alpha-GPC combined with donepezil preserved brain volume better than donepezil alone over three years. The consistency of this signal across multiple ASCOMALVA time points is noteworthy, but because this is combination therapy, alpha-GPC's independent contribution cannot be isolated. The full methodological assessment of the ASCOMALVA data is in the "How Strong Is the Evidence?" section.
Alpha-GPC's long-term brain protection evidence comes from a very different kind of study. Rather than a controlled experiment, researchers tracked over half a million people with early memory problems through a national health database and found that those who used alpha-GPC were somewhat less likely to develop Alzheimer's or vascular dementia. That's a meaningful signal given the enormous sample size, but it doesn't prove alpha-GPC caused the protection. People prescribed alpha-GPC may have been different from those who weren't in ways the study couldn't account for. In another set of studies, alpha-GPC was always given alongside a dementia drug, so we can't tell how much benefit came from alpha-GPC alone.
Citicoline has the more complete neuroprotection story, but "more complete" is relative. It supplies building materials for brain cell membranes that alpha-GPC doesn't, it appears to support multiple neurotransmitter systems beyond just acetylcholine, and it has decades of stroke rehabilitation research behind it. Those are several independent lines of evidence all pointing the same direction.
Alpha-GPC's neuroprotection data comes from a different kind of evidence: a massive observational study tracking over half a million people showed lower dementia conversion rates among users. That's a real signal, but observational data can't prove causation. The other long-term data always combined alpha-GPC with a dementia drug, so we can't separate what alpha-GPC did on its own.
Neither compound has a long-term controlled trial in healthy adults. If you're supplementing for brain protection over years, citicoline has more reasons to be optimistic, but honest confidence in either compound for this purpose is still moderate at best.
Alpha-GPC vs Citicoline for Exercise Performance
Alpha-GPC is the only compound with controlled exercise data. Exercise performance in the context of choline supplementation refers to measurable physical outputs (strength, power, explosive speed) and the hormonal responses (particularly growth hormone) that supplement marketing frequently claims. Citicoline has not been studied for exercise outcomes, though a mechanistic case exists through acetylcholine's role at the neuromuscular junction. This section evaluates the alpha-GPC evidence on its own terms.
Two PubMed-indexed RCTs have reported positive strength or power findings. Bellar et al. (2015) gave 13 college-aged males 600 mg/day of alpha-GPC for six days in a double-blind, placebo-controlled, crossover design. The alpha-GPC group produced significantly greater peak force on the isometric mid-thigh pull compared to placebo. Upper body isometric force trended positive but did not reach significance.
Marcus et al. (2017) expanded this in a larger sample. 48 college-aged males received 250 mg or 500 mg of alpha-GPC daily, caffeine (200 mg), or placebo for seven days. No differences were found for isometric mid-thigh pull or upper body strength. However, the 250 mg group showed significantly greater countermovement jump velocity and mechanical power compared to placebo. The higher 500 mg dose did not outperform the lower dose on this measure, which complicates a straightforward dose-response interpretation.
A third trial complicates the picture further. Kerksick 2024 (detailed in the Focus section) measured vertical jump and bench press throw in addition to cognitive outcomes. Neither physical measure showed significant effects at either dose. This is the largest of the three trials and the only one conducted independently of the Bellar research group.
The inconsistency across studies deserves attention. Bellar found isometric strength gains at 600 mg that Marcus did not replicate. Marcus found explosive power gains at 250 mg that Kerksick did not replicate. All three samples were small (13, ~12 per group, and 20 respectively), and Bellar and Marcus come from overlapping research teams. This is not a pattern of consistent replication. It is three small studies with partially contradictory results.
Three studies have tested whether alpha-GPC helps with physical performance, and they don't agree with each other. One found it helped with pulling strength but not pushing. Another found it helped with jumping power but not pulling strength. The third, and largest, found no physical benefits at all. Each study was small (13 to 48 people), and two came from the same research group. When small studies produce mixed results like this, it usually means the effect, if it exists, is small and inconsistent. This isn't a blank slate (there are some positive signals), but it's far from the reliable performance boost that supplement marketing often suggests.
The growth hormone claim does not hold up under controlled testing. Alpha-GPC is widely promoted in fitness communities for boosting growth hormone release. The claim traces to a single small study (seven subjects, one dose combined with exercise) that has never been replicated in a larger sample and is not indexed in PubMed, making independent verification difficult. Kerksick 2024 specifically measured growth hormone response and found no significant effect at either 315 mg or 630 mg.
If growth hormone is your reason for considering alpha-GPC, the most rigorous controlled evidence does not support that use.
You may have seen alpha-GPC marketed as a natural growth hormone booster for building muscle. That claim comes from one tiny study with seven people that isn't even in the main medical research database. When a proper controlled trial actually measured growth hormone levels after alpha-GPC supplementation, there was no effect. If you're considering alpha-GPC specifically because you want higher growth hormone, the best available evidence says it won't deliver that.
Neither compound is a well-supported exercise supplement right now. Alpha-GPC has three small trials with contradictory results: one found strength benefits, another found power benefits, and the largest found nothing. That's not the kind of consistency you want to see before adding something to your training stack.
The growth hormone angle is even weaker. That claim traces back to a single tiny study that isn't even indexed in the main medical databases. When a proper controlled trial measured growth hormone after alpha-GPC, there was no effect. If GH is your reason for considering alpha-GPC, the data doesn't support it.
Citicoline hasn't been studied for exercise at all. If physical performance is your primary goal, the current evidence doesn't make a strong case for either compound.
Across all four outcome categories, citicoline has a broader evidence base: multiple oral trials spanning ages 13 to 85, both sexes, and independent research groups across memory, focus, and neuroprotection. Alpha-GPC has a fast-acting cognitive signal from a single acute study, promising large-scale observational neuroprotection data, and preliminary exercise findings that remain inconsistent. Neither compound has a long-term trial lasting 12 months or longer in healthy adults, and no head-to-head oral comparison has ever been conducted. But how much of this evidence actually applies to the way you'd use these supplements? That question requires looking beyond the outcome data and into the strength and applicability of the underlying studies themselves.
How Strong Is the Evidence for Alpha-GPC vs Citicoline?
This section examines whether the evidence people cite for these compounds actually applies to oral supplement use. The short version: a large proportion of alpha-GPC's literature used injection (not oral dosing) or combination therapy (not standalone use). Once you filter for oral evidence in healthy adults, citicoline has seven or more controlled trials spanning decades; alpha-GPC has two, both from 2024. That doesn't make alpha-GPC ineffective, but it means the two compounds are at very different stages of clinical characterization.
Read the full evidence analysis
The previous sections evaluated each compound's evidence within specific outcome categories. This section steps back and asks a different question: how much of the evidence people cite for these compounds actually applies to the way you'd use them? The answer requires looking at study design, route of administration, and evidence volume, not just whether results were positive.
The Route-of-Administration Problem
The single most important methodological issue in this comparison is that a large proportion of alpha-GPC's clinical literature used intramuscular injection rather than oral supplementation. This distinction matters more than most supplement reviews acknowledge.
Intramuscular injection bypasses the gastrointestinal tract entirely. The compound enters circulation without being exposed to digestive enzymes, gut bacteria, or first-pass hepatic metabolism. For alpha-GPC specifically, recent research has identified an intestinal enzyme (Gpcpd1) that actively cleaves oral alpha-GPC into free choline before it can be absorbed intact (Chen et al. 2024). This means oral alpha-GPC undergoes a metabolic step that IM alpha-GPC never encounters. Results from IM studies do not straightforwardly predict what happens after oral dosing, because the molecule arriving in circulation may be fundamentally different.
This is not a theoretical concern. As covered in the Pharmacokinetics section, no study has ever detected intact alpha-GPC in human plasma after oral dosing. The compound appears to be fully hydrolyzed before absorption. By contrast, citicoline's oral bioavailability is well-characterized across multiple studies spanning four decades, with absorption essentially complete (Dinsdale et al. 1983, Secades 2006).
This asymmetry does not mean oral alpha-GPC is ineffective. The two oral trials that exist (Kerksick 2024, Jeon 2024) are both positive. Free choline itself is the active precursor for acetylcholine synthesis, so oral alpha-GPC's mechanism of action (delivering a large bolus of free choline) remains plausible regardless of whether the parent molecule survives digestion. But when you encounter a claim about alpha-GPC's clinical efficacy, checking whether the underlying study used injection or oral dosing is a necessary filter. The majority of the older and more widely cited alpha-GPC literature, including all three trials in the only head-to-head meta-analysis, used injection.
The 2025 Head-to-Head Meta-Analysis
Several competitor pages and supplement forums cite Sagaro and Amenta 2025 as evidence that alpha-GPC is the superior compound. The headline result does favor alpha-GPC: across three randomized controlled trials comparing alpha-GPC directly against citicoline in dementia patients, alpha-GPC significantly outperformed citicoline on overall clinical ratings. That sounds definitive. It is worth understanding what sits beneath that headline.
Three methodological limitations significantly constrain what this meta-analysis tells oral supplement users.
First, all three included trials used intramuscular dosing. They were conducted in 1991, in elderly patients with vascular dementia, using open-label (unblinded) designs. The route-of-administration problem described above applies in full: these results describe what happens when you inject both compounds, not what happens when you swallow them.
Second, the alpha-GPC groups received substantially more choline. At equal milligram doses, alpha-GPC delivers roughly 40% choline by weight versus citicoline's 18%. This means the alpha-GPC arms received approximately 2.2 times more choline than the citicoline arms at the same nominal dose. Any difference in outcomes could reflect a straightforward dose-response relationship (more choline producing more acetylcholine) rather than a fundamental mechanistic advantage. A fair pharmacological comparison would require equimolar choline dosing, which none of these trials used and which no trial has ever used.
Third, the advantage appeared only on subjective clinician ratings, not objective cognitive tests. The primary outcome favoring alpha-GPC was the SCAG scale, a clinician-rated global impression measure. On the Wechsler Memory Scale and word fluency tests (standardized, objective cognitive assessments), there was no significant difference between compounds. In an open-label trial (where both clinician and patient know which treatment is being given), subjective ratings are particularly susceptible to expectation bias. Objective tests are not.
Together, this meta-analysis answers a very specific question: when given by IM injection at unequal choline delivery to elderly vascular dementia patients in unblinded conditions, alpha-GPC produced better clinician-rated impressions than citicoline, with no difference on objective cognitive tests. Whether this translates to oral supplementation in healthy adults is a fundamentally different question that this meta-analysis was not designed to answer.
The Combination Therapy Problem
Alpha-GPC's longest-running clinical evidence comes from the ASCOMALVA trial series (2012–2020), which tested alpha-GPC combined with donepezil (a prescription acetylcholinesterase inhibitor) against donepezil alone in Alzheimer's patients. The combination consistently outperformed donepezil alone on cognitive scores, behavioral symptoms, and brain volume preservation over two to three years.
These are real, consistent findings over a meaningful time horizon. The methodological problem is isolation: you cannot determine how much of the benefit came from alpha-GPC versus the pharmacological interaction between alpha-GPC and donepezil. Acetylcholinesterase inhibitors work by preventing acetylcholine breakdown. Alpha-GPC increases acetylcholine production. Combining them creates a synergistic effect where more acetylcholine is produced and less is degraded simultaneously. This synergy is pharmacologically predictable but tells you nothing about what alpha-GPC does alone.
The ASCOMALVA data supports the claim that "alpha-GPC is a useful adjunct to donepezil in Alzheimer's disease." It does not support the broader claim that "alpha-GPC alone produces long-term cognitive or neuroprotective benefits," which is the relevant question for someone choosing a supplement.
How Much Oral Evidence Actually Exists?
Stripped of IM studies and combination therapy, here is what each compound has in the context that matters for supplement users: oral dosing, either as monotherapy or as the only active variable.
Citicoline oral evidence in healthy adults: Four or more placebo-controlled trials (Nakazaki 2021, Al-Kuraishy 2020, McGlade 2012, McGlade 2019) testing memory, attention, and processing speed in populations spanning ages 13 to 85 and both sexes, from multiple independent research groups across different countries. Additionally, the University of Ottawa group (Knott 2014, 2015) has produced three single-dose studies showing acute neurophysiological and cognitive effects in healthy men, effects that are notably baseline-dependent, appearing strongest in low performers.
Alpha-GPC oral evidence in healthy adults: One acute single-dose study (Kerksick 2024) in 20 young men, showing Stroop test improvement within 60 minutes. This is the entire oral evidence base for alpha-GPC in cognitively healthy people.
Alpha-GPC oral evidence in cognitive impairment: One 12-week trial (Jeon 2024) in 100 MCI patients, showing significant ADAS-cog improvement versus placebo. Positive, but a different population than healthy supplement users.
Citicoline in cognitive impairment and dementia: Multiple trials plus meta-analyses (Bonvicini 2023), spanning decades, almost all oral.
Pharmacokinetic evidence asymmetry: Citicoline has three human PK studies spanning four decades (Wurtman 2000, Dinsdale 1983, Sarkar 2012), plus extensive review coverage establishing its biphasic absorption profile, uridine time-course, and near-complete oral bioavailability. Alpha-GPC has a single bioequivalence study (Min et al. 2019) at one dose in one population, with high inter-individual variability and no dose-response, food-effect, or steady-state data. For a compound sold globally as both a supplement and a prescription drug, this is a remarkably thin pharmacokinetic evidence base.
This asymmetry is itself a finding. It does not make alpha-GPC ineffective. Both of its oral trials are positive. But it means the two compounds are at fundamentally different stages of clinical characterization. Citicoline's oral evidence base has been built over decades across multiple populations, research groups, and countries. Alpha-GPC's oral evidence base is essentially two trials from 2024.
Gaps That Apply to Both Compounds
Honest assessment requires acknowledging what neither compound has demonstrated:
No head-to-head oral comparison trial has ever been conducted. No one has given one group oral alpha-GPC and another group oral citicoline and measured the same cognitive outcomes. Everything in this article (and every other comparison article) is inference from separate trials with different designs, populations, and endpoints.
No long-term supplementation study (12 months or longer) has been published for either compound in healthy adults. The longest healthy-adult trials are 12 weeks (Nakazaki 2021 for citicoline, Jeon 2024 for alpha-GPC in MCI). For anyone taking these compounds as a years-long neuroprotective strategy, the evidence is extrapolated from shorter-term data and mechanistic reasoning.
No trial has compared the two at equimolar choline doses, which would be the only fair direct pharmacological comparison. Every existing comparison, including the Sagaro meta-analysis, compared equal milligram doses that delivered unequal amounts of choline.
Most citicoline trials used Cognizin (Kyowa Hakko's branded form) and were industry-funded. The designs are generally rigorous and outcomes pre-registered, but industry funding is a relevant disclosure for evidence assessment.
Most alpha-GPC exercise performance trials come from overlapping research groups, limiting the independence of the replication signal.
The upshot is that these two compounds are at fundamentally different stages of clinical characterization. Citicoline has seven or more controlled oral trials across diverse populations, spanning multiple decades and independent research groups. Alpha-GPC has two oral trials, both from 2024 and both positive. Its broader literature is real but built largely on injection studies and combination therapy that don't tell you what an oral capsule will do.
That doesn't make alpha-GPC ineffective. It means citicoline's advantage here is "more evidence, built over more time" rather than "proven superior compound." Alpha-GPC's evidence base is younger, not negative. But evidence strength is only half the picture. The other half is safety, and that's where a different kind of asymmetry emerges.
The Safety Question: TMAO and Cardiovascular Risk
Both alpha-GPC and citicoline are generally well-tolerated. The common side effects for both are mild: occasional headache, digestive discomfort, and insomnia at higher doses. But there is a safety dimension that separates these two compounds in a way the efficacy data alone does not capture. Understanding it requires working through several layers of evidence, from molecular mechanism to population-level epidemiology. The honest conclusion is more complex than either "alpha-GPC is dangerous" or "the risk is overblown."
How Choline Becomes TMAO
When choline-containing compounds reach the large intestine, gut bacteria can convert free choline into trimethylamine (TMA). TMA is absorbed into the bloodstream and oxidized in the liver into trimethylamine N-oxide (TMAO). Elevated circulating TMAO has been associated with atherosclerosis, increased platelet reactivity, and higher cardiovascular event risk in observational studies.
The critical variable is how much free choline reaches colonic bacteria. Different choline forms differ dramatically in this regard.
The strongest human evidence comes from Wilcox et al. 2021. Healthy volunteers received either free choline (as choline bitartrate) or phospholipid-bound choline (as phosphatidylcholine in egg yolks) at equivalent choline doses. The choline bitartrate group saw plasma TMAO levels rise 5.8-fold. The phosphatidylcholine group saw no significant increase. The same trial measured platelet reactivity: the free choline group showed increased platelet aggregation, a direct pro-thrombotic effect measured in a controlled human setting.
Why Alpha-GPC Is Expected to Raise TMAO
Alpha-GPC releases a high proportion of free choline in the gut. The pathway from alpha-GPC to TMAO is now characterized at multiple levels.
Shirouchi et al. (2022) gave rats alpha-GPC, choline chloride, or phosphatidylcholine at matched choline doses for four weeks. Alpha-GPC and choline chloride raised plasma and urinary TMAO significantly. Phosphatidylcholine did not. This confirms the broader principle: water-soluble choline forms that deliver free choline to gut bacteria raise TMAO, while lipid-bound forms that are absorbed upstream do not.
A 2024 study identified a specific molecular mechanism that strengthens this picture. Chen et al. discovered that Gpcpd1, an enzyme expressed in the intestinal lining, actively cleaves alpha-GPC into free choline before gut bacteria even encounter it. This means the body has a dedicated enzymatic step that converts alpha-GPC into exactly the form of choline that gut bacteria use to produce TMA. There are multiple redundant pathways for this conversion.
One important caveat: no published study has directly measured plasma TMAO levels in humans specifically after alpha-GPC supplementation. The animal evidence is strong and the enzymatic mechanism is well-characterized, but the direct human measurement remains a gap.
Why Citicoline May Not Raise TMAO
Citicoline's molecular structure provides a plausible explanation for why it has not shown the same TMAO signal. When citicoline is hydrolyzed in the body, the choline it releases remains phosphorylated, still bound to a phosphate group. This reduces the proportion of free choline available to gut bacteria for TMA conversion.
Synoradzki and Grieb (2019) argued that citicoline's pyrophosphate bond provides superior metabolic protection compared to alpha-GPC's ester bond, limiting gut-level choline liberation. This structural difference is consistent with the broader pattern from the Wilcox and Shirouchi data: phospholipid-bound and phosphorylated choline forms do not raise TMAO, while free choline forms do.
The same caveat applies in reverse. No study has directly measured TMAO production from citicoline supplementation in humans. The advantage is mechanistically plausible and consistent with analogous evidence from other phosphorylated choline forms, but it has not been specifically confirmed for citicoline itself.
Is TMAO a Cause of Heart Disease or Just a Marker?
The strength of the safety distinction between these compounds depends partly on how seriously we take TMAO as a cardiovascular threat, and that question is scientifically unsettled.
The statistical association is robust. Meta-analyses report meaningfully elevated cardiovascular event risk and all-cause mortality in people with elevated TMAO levels (Heianza et al. 2017: RR 1.62 for major adverse cardiovascular events, RR 1.63 for all-cause mortality comparing highest vs. lowest TMAO quartiles).
The case for TMAO as a causal agent is real. In animal models, TMAO directly promotes atherosclerotic plaque formation through mapped molecular pathways: it activates NF-κB and MAPK inflammatory cascades, upregulates scavenger receptors on macrophages (promoting foam cell formation), and enhances vascular inflammation. In humans, the Wilcox 2021 trial demonstrated that free choline supplementation increased both TMAO and platelet reactivity in healthy people, a direct pro-thrombotic effect linked to the same dietary intervention that raised TMAO.
The case for TMAO as a marker rather than a cause is also substantial. TMAO is primarily cleared by the kidneys. When studies adjust for renal function, the TMAO-cardiovascular association often weakens or disappears entirely, suggesting elevated TMAO may reflect impaired kidney function (which independently raises cardiovascular risk) rather than causing damage itself. Mendelian randomization studies have found that genetically elevated plasma choline was associated with cardiovascular risk, but genetically elevated TMAO itself showed no significant causal effect after sensitivity analyses. And fish contains 46 to 62 times more TMAO than eggs, yet fish consumption reduces cardiovascular risk. This is a paradox that suggests TMAO's role is more complex than a simple toxin model.
The most balanced reading: TMAO is a genuine biomarker associated with cardiovascular risk, likely with some direct pro-inflammatory and pro-thrombotic effects, but its role as an independent causal driver of cardiovascular disease remains unproven. For the purpose of choosing between choline supplements, the TMAO signal is worth taking seriously without being treated as settled science in either direction.
What Population Studies Show About Alpha-GPC and Stroke Risk
The population-level data tells a more complex story than either side of the debate typically presents.
Lee et al. 2021 is the most cited study: a large population-based cohort using the South Korean National Health Insurance Service database, following over 12 million individuals aged 50 and older for 10 years. After adjusting for traditional cerebrovascular risk factors, alpha-GPC users showed significantly higher risk of total stroke (adjusted hazard ratio: 1.43), ischemic stroke (aHR: 1.34), and hemorrhagic stroke (aHR: 1.37). The association showed a dose-response pattern: longer duration of alpha-GPC use was linked to higher risk.
Kim et al. 2025 examined a different population and found a different pattern. In 508,107 MCI patients from the same database, alpha-GPC users showed 10% lower Alzheimer's conversion risk and 17% lower vascular dementia conversion risk. On stroke, a time-dependent Cox regression analysis showed a protective signal (HR: 0.833 ischemic, 0.847 hemorrhagic), contradicting Lee 2021. But when the authors applied propensity score matching as a sensitivity analysis, the stroke protection disappeared. The apparent benefit was likely driven by baseline differences between groups rather than a true protective effect.
These studies examined different populations (general population aged 50+ vs. MCI patients only), and confounding by indication affects both differently. They are not directly contradictory, but they do not agree. Neither examined oral supplement users specifically; both tracked prescription alpha-GPC in South Korean clinical populations. For healthy adults considering oral supplements, the Lee 2021 signal is the more directly relevant reference point because it studied a broader population. The Kim 2025 data adds important nuance: the picture is more complex than "alpha-GPC causes strokes." But it does not eliminate the concern.
Citicoline's Safety Profile
Citicoline has not shown a comparable stroke or cardiovascular risk signal in any study. Its clinical history provides a form of long-term safety evidence that is different from a controlled trial but meaningful in its own right: decades of use in stroke rehabilitation research involving thousands of patients across multiple countries. A compound that reliably worsened cardiovascular outcomes would not have survived this volume of clinical scrutiny in precisely the population where cardiovascular harm would be most visible.
The Zhao et al. 2025 network meta-analysis (covered in the Long-Term Neuroprotection section) found that citicoline improved neurological function and reduced mortality in acute ischemic stroke patients across 13 studies. This does not prove citicoline is cardioprotective, but the absence of a negative safety signal across thousands of high-risk patients is substantial evidence, even if it is not a formal safety proof.
Citicoline's limitations deserve acknowledgment here too. No direct TMAO measurement in humans exists. Its structural advantage in limiting free choline release is mechanistically plausible but unconfirmed by direct measurement. And citicoline delivers roughly 18% choline by weight compared to alpha-GPC's 40%, so it is generating less free choline by default at standard doses. Some of the apparent safety advantage may simply be a lower-dose effect rather than a structural one.
Well-characterized TMAO production pathway that may carry cardiovascular implications. Epidemiological stroke data is mixed: elevated risk in the general population (Lee 2021), no clear signal in MCI patients (Kim 2025). The Wilcox 2021 finding of increased platelet reactivity is a direct pro-thrombotic signal.
Molecular structure plausibly avoids the TMAO pathway, though neither compound's TMAO production has been directly measured in humans. Decades of use in stroke rehabilitation provide substantial safety evidence from the population where cardiovascular harm would be most visible.
The weight of current evidence favors citicoline on cardiovascular safety. Alpha-GPC has a well-established TMAO production pathway and a mixed but concerning epidemiological stroke signal. Citicoline has neither.
Alpha-GPC vs Citicoline: Side-by-Side Comparison
This table summarizes the evidence covered in the preceding sections. It is a reference tool, not a substitute for the full analysis. Where a row says "Edge," that reflects the weight of current evidence, not a definitive superiority claim.
| Alpha-GPC | Citicoline (CDP-Choline) | Edge | |
|---|---|---|---|
| Choline content | ~40% by weight | ~18% by weight | Alpha-GPC |
| Unique secondary component | Glycerophosphate (modest membrane phospholipid contribution) | Uridine (via cytidine): Kennedy pathway substrate for synaptic membrane synthesis | Citicoline |
| Primary mechanism | Concentrated choline delivery → acetylcholine synthesis | Choline + uridine → acetylcholine + Kennedy pathway phospholipid production | Citicoline |
| Onset profile | Evidence of acute cognitive effects within 60 minutes (Kerksick 2024, single dose, n=20) | Acute neurophysiological effects documented (Knott 2014, 2015; baseline-dependent). Memory and attention benefits build over 2–12 weeks of daily use. | Context-dependent |
| Memory and cognition | Positive in MCI (Jeon 2024, oral, n=100). No oral data in healthy adults. | Multiple oral trials in healthy adults aged 13–85, both sexes (Nakazaki 2021, Al-Kuraishy 2020, McGlade 2012, McGlade 2019). Consistent positive signals. | Citicoline |
| Focus and processing speed | Stroop test improvement within 60 minutes at both doses tested (Kerksick 2024, n=20 young men). No effect on N-Back or Flanker. | Sustained attention improvements over 2–4 weeks across multiple populations (McGlade 2012, 2019; Al-Kuraishy 2020). Acute effects baseline-dependent (Knott 2015). | Different profiles |
| Long-term neuroprotection | Observational: 10% lower Alzheimer's conversion, 17% lower vascular dementia conversion in MCI cohort (Kim 2025, n=508K). ASCOMALVA combo therapy showed brain volume preservation. | Kennedy pathway mechanism for structural maintenance. Multi-neurotransmitter profile. Stroke rehabilitation evidence across decades. Oxidative stress reduction (Al-Kuraishy 2020). Largest acute stroke trial (ICTUS) was negative. | Citicoline (moderate evidence advantage) |
| Exercise performance | Preliminary positive signals for lower body force/explosive power in 2 small RCTs (Bellar 2015, Marcus 2017); not confirmed in Kerksick 2024. Growth hormone: not supported. | Not studied | Alpha-GPC (preliminary) |
| Oral evidence volume in healthy adults | 1 acute trial (Kerksick 2024, n=20 young men) | 4+ multi-week trials spanning ages 13–85, both sexes, multiple research groups. 3 additional acute single-dose studies (Knott group). | Citicoline |
| TMAO production | Well-characterized pathway: Gpcpd1 enzyme cleaves alpha-GPC to free choline in gut → bacterial conversion to TMA → hepatic oxidation to TMAO (animal and mechanistic evidence; no direct human TMAO measurement after alpha-GPC) | Phosphorylated choline release limits gut bacterial access. Structurally consistent with non-TMAO-producing choline forms. Not directly measured in humans. | Citicoline (mechanistic) |
| Cardiovascular safety signal | Lee 2021 (12M+ cohort): elevated stroke risk (aHR 1.43). Kim 2025 (MCI cohort): no elevated risk after adjustment. Mixed overall. | No cardiovascular safety signal in any study. Decades of use in stroke rehabilitation research without adverse cardiovascular findings. | Citicoline |
| Most common research dose | 300–1,200 mg/day oral; 1,000 mg/day IM in older trials | 250–2,000 mg/day; 500 mg/day is the most studied oral dose | Informational |
The table above captures where the evidence currently stands. What it cannot capture is how to translate these findings into a practical decision based on your specific goals. That is what the next section addresses.
Citicoline and Alpha-GPC Dosage, Timing, and How to Choose
You now understand what each compound is, how they compare on outcomes, and where the safety data falls. The recommendations below integrate all three dimensions: efficacy, mechanism, and safety.
NeuroVesa sells a citicoline-containing supplement. We have evaluated both compounds against the clinical evidence throughout this article. Where the evidence favors alpha-GPC, we have said so. We believe the analysis is objective, but we want to disclose the potential conflict of interest and let you judge for yourself.
Which One Should You Take: Alpha-GPC or Citicoline?
The table below maps your goal to the best-supported option, dose, and key evidence.
| If your goal is... | Best option | Dose | Timing / Frequency | Key evidence | Safety note |
|---|---|---|---|---|---|
| Sharper memory as you age | Citicoline | 500 mg/day | Morning, daily. Effects build over 4–12 weeks. | Nakazaki 2021: significant episodic memory improvement in adults 50–85 at 500 mg/day for 12 weeks. Three additional healthy-adult RCTs confirm the pattern. | Well tolerated up to 2,000 mg/day in clinical studies. Minimal TMAO concern based on molecular structure. |
| Sustained focus and attention | Citicoline | 250–500 mg/day | Daily, ongoing. Benefits appear over 2–4 weeks. | McGlade 2012: attentional benefits at 250 mg/day. McGlade 2019: improved motor speed and attention at 250–500 mg/day. Al-Kuraishy 2020: improved vigilance and reaction time. All oral, all healthy adults. | Same favorable safety profile. |
| Acute cognitive boost (exam, presentation, deadline) | Alpha-GPC | 315–630 mg (single dose) | 60 minutes before the demanding task. As needed, not daily. | Kerksick 2024: Stroop test improvement within 60 minutes at both doses in healthy young men. One small trial (n=20). Note: citicoline also has acute single-dose data (Knott 2015), but effects are baseline-dependent and less consistent. | TMAO production expected even at single doses based on the mechanistic pathway. Occasional use limits cumulative exposure. Only studied in young men; not tested in women or adults over 35. |
| Exercise performance (strength/power) | Alpha-GPC | 300–600 mg (single dose) | 60–90 minutes before training. As needed. | Bellar 2015: increased lower body isometric force (n=13, 600 mg/day, 6 days). Marcus 2017: increased jump velocity and power (n=48, 250 mg). Kerksick 2024: no effect on vertical jump or bench press throw (n=20). Results inconsistent across trials. Growth hormone effects not supported. | TMAO pathway applies. Occasional pre-workout use limits cumulative exposure. All three trials enrolled only young men. Evidence is preliminary and inconsistent, not strong enough for a confident recommendation, but alpha-GPC is the only compound with any data in this space. |
| Long-term neuroprotection | Citicoline (+ DHA) | 500 mg/day citicoline + DHA-rich fish oil | Daily, ongoing. This is a years-long strategy. | Kennedy pathway: citicoline provides uridine, the limiting substrate for synaptic membrane synthesis. Preclinical data (Wurtman 2010, 2014): the three-substrate combination (uridine + choline + DHA) restored synapse density in aged rats. No human combination trial exists. Stroke rehabilitation evidence supports the broader neuroprotective profile. | Citicoline carries no TMAO concern. DHA has well-established cardiovascular safety. The combination supplies all three Kennedy pathway substrates. |
| Cardiovascular safety priority | Citicoline | 500 mg/day | Daily | Citicoline's molecular structure keeps choline phosphorylated, reducing free choline available to gut bacteria (Synoradzki & Grieb 2019). Consistent with the broader pattern that lipid-bound and phosphorylated choline forms do not raise TMAO (Wilcox 2021, Shirouchi 2022). No direct TMAO measurement for citicoline exists. | The clear choice for readers with CVD risk factors: age 45+, hypertension, diabetes, or family history of cardiovascular disease. |
| Stacking with omega-3 / DHA | Citicoline + DHA fish oil | 500 mg/day citicoline + standard DHA dose | Daily, both taken together or at the same meal. | Citicoline provides choline + uridine; DHA completes the Kennedy pathway substrate set. Preclinical data showed the combination outperformed any pair. No human trial exists. | Both compounds have strong safety profiles. No known interaction. |
| Cognitive support for MCI | Either (with medical guidance) | Citicoline: 500–1,000 mg/day. Alpha-GPC: 600 mg/day. | Daily, ongoing. Discuss with your healthcare provider. | Alpha-GPC: Jeon 2024 (oral, 600 mg/day, significant ADAS-cog improvement in MCI). Citicoline: Bonvicini 2023 meta-analysis (positive across dementia populations). ASCOMALVA series: alpha-GPC + donepezil outperformed donepezil alone (combination therapy, so we cannot isolate alpha-GPC's contribution). | Alpha-GPC: TMAO pathway applies. Citicoline: well tolerated. MCI warrants medical oversight regardless of supplement choice. |
A note on what this table leaves out. Two use cases are excluded because the evidence does not support placing them in a recommendation table. Stroke recovery: real evidence exists for citicoline, but this requires medical management and is not a self-directed supplementation decision. Psychiatric conditions (ADHD, depression, anxiety): the data for both compounds is too preliminary for dosing guidance. If either of these is your primary concern, the current evidence base does not support self-directed supplementation.
The Bottom Line
If you've read this far, you've seen the full picture. Here's the simplest version.
Citicoline has the broader and more directly relevant evidence base for most cognitive goals. It's been tested in healthy adults across a wide age range, it delivers uridine that alpha-GPC can't provide, and it has a cleaner cardiovascular safety profile. For most people, daily citicoline is the single best-supported starting point.
Alpha-GPC has a narrower but real role. It's the only compound with evidence for acute, single-dose cognitive effects, making it better suited for specific high-demand situations: a final exam, a major presentation, a competition day. Some people also use it pre-workout for a potential edge on heavy strength sessions, though the exercise evidence is still inconsistent. If you're looking for something to keep in the toolkit for occasional use rather than daily supplementation, alpha-GPC is the option with data behind it.
We'll be direct about one thing: NeuroVesa sells a citicoline-containing supplement, and this conclusion favors citicoline. We've tried to let the evidence lead throughout this article, including where it favors alpha-GPC (acute cognitive effects, exercise performance signals). If you think the conflict of interest biases this analysis, every study cited above is linked to PubMed so you can read the primary sources and decide for yourself.
What neither compound has: a long-term trial in healthy adults lasting a year or more, a direct head-to-head comparison, or enough evidence to call anything in this space settled. We're working with the best available data, and it's better than most supplement categories, but it's still early.
The evidence will keep evolving. We'll update this article as new research publishes.
Citicoline vs Alpha-GPC: Frequently Asked Questions
Can I take alpha-GPC and citicoline together?
No trial has tested the combination. The theoretical appeal is alpha-GPC for acute sharpness plus citicoline for long-term structural support, but there are practical downsides. Both deliver choline to the brain, so you're doubling up on one input while citicoline's unique benefit (uridine) is already fully covered on its own. Adding alpha-GPC also introduces its TMAO pathway, which citicoline alone avoids. If you want both, the most logical approach is daily citicoline (500 mg) with occasional alpha-GPC (315-630 mg) only on high-demand days. That limits TMAO exposure while preserving alpha-GPC's acute advantage. But this protocol has never been tested. For most people, citicoline alone at 500 mg/day covers the broadest range of goals with the fewest trade-offs.
How much choline is in alpha-GPC vs citicoline?
Alpha-GPC is roughly 40% choline by weight: a 600 mg dose delivers about 240 mg of choline. Citicoline is roughly 18%: a 500 mg dose delivers about 90 mg. Citicoline's primary value comes from the uridine component, not raw choline quantity.
Does alpha-GPC cause stroke?
The evidence is mixed. Lee 2021 tracked over 12 million people and found 43% higher stroke risk in alpha-GPC users over 10 years. Kim 2025 (MCI cohort) found no clear stroke risk after adjustment. Both are observational; causation is unproven. The TMAO mechanism is biologically plausible. If you have cardiovascular risk factors, citicoline avoids this uncertainty.
Does citicoline increase dopamine?
There are real signals. Citicoline's uridine component influences dopamine through P2Y receptor signaling and changes in neuronal membrane composition. One animal study (Wang 2005) measured a 20% increase in dopamine release in aged rats, and human neuroimaging studies show functional changes in dopamine-related brain regions after citicoline use. What is missing is a human trial that directly measures brain dopamine levels, so calling citicoline a "dopamine booster" goes further than the data currently supports. The stronger, better-documented benefits are for memory, attention, and neuroprotection.
How long does it take for citicoline or alpha-GPC to work?
Alpha-GPC's attention effects can appear within 60 minutes of a single dose (Kerksick 2024). Citicoline also has acute single-dose data showing neurophysiological and cognitive effects within hours (Knott 2014, 2015), though these effects are baseline-dependent, strongest in people with lower baseline cognitive performance. Citicoline's memory and attention benefits in the broader trial literature build over 2 to 12 weeks of daily use. The timeframe depends on your goal.
What is the recommended dosage for citicoline and alpha-GPC?
Citicoline: 500 mg/day for daily cognitive support, the most evidence-backed dose. Alpha-GPC: 315–630 mg as a single dose for acute needs, or 600 mg/day for ongoing MCI support. The decision table in the Practical Guide provides goal-specific breakdowns with supporting evidence.
Who should not take alpha-GPC or citicoline?
Both compounds are generally well tolerated, but several groups should exercise caution. Anyone taking anticoagulant or antiplatelet medications should consult their physician, since choline can interact with these drugs. Pregnant and breastfeeding women should discuss supplementation with their provider; while choline itself is essential during pregnancy, the safety of high-dose alpha-GPC and citicoline specifically has not been established in this population. Children should only use these supplements under medical guidance, as most clinical trials enrolled adults. For people with existing cardiovascular disease or significant CVD risk factors, citicoline is the safer choice given alpha-GPC's TMAO pathway and the Lee 2021 stroke data.
Is alpha-GPC or citicoline better for exercise performance?
Alpha-GPC has more data, though the evidence is preliminary and inconsistent. Two small RCTs (Bellar 2015, Marcus 2017) found positive effects on lower body force or explosive power. A third trial (Kerksick 2024) found no effects on vertical jump, bench press throw, or growth hormone. The growth hormone claim that appears frequently in fitness marketing is not supported by controlled evidence. Citicoline has not been studied for exercise performance. If physical performance is your primary goal, the evidence is too early-stage for a confident recommendation for either compound.
Is choline bitartrate as good as alpha-GPC or citicoline?
Choline bitartrate is the cheapest supplemental choline form, roughly 41% choline by weight. However, it does not cross the blood-brain barrier as efficiently as either alpha-GPC or citicoline. Most of its choline is metabolized peripherally for liver function and general methylation rather than being preferentially delivered to the brain. As a source of free choline, it also feeds the same TMAO production pathway as alpha-GPC. The Wilcox 2021 trial specifically tested choline bitartrate and found it raised TMAO 5.8-fold while increasing platelet reactivity. For brain-specific goals, alpha-GPC and citicoline are better tools. For general choline adequacy on a budget, choline bitartrate works. For anyone with cardiovascular risk factors, citicoline avoids the TMAO pathway that both alpha-GPC and choline bitartrate share.
Does citicoline help with stroke recovery?
Citicoline has meaningful evidence in this space. The Zhao 2025 network meta-analysis ranked citicoline among the more effective neuroprotective agents across 13 acute ischemic stroke trials, though the largest single trial (ICTUS) was negative. It has been used in post-stroke rehabilitation research for decades, typically at doses of 500 to 2,000 mg per day. If this is relevant to your situation, discuss it with a neurologist. Citicoline is a supplement, not a substitute for standard medical treatment.
Can I take citicoline with omega-3 fish oil (DHA)?
Yes, and this is one of the more evidence-supported supplement combinations. Citicoline provides choline and uridine, two of the three substrates for the Kennedy pathway. DHA completes the set. Preclinical research showed the three-substrate combination was more effective than any pair for synapse building. No human combination trial exists yet. See the Practical Guide for dosing.
Should I take citicoline in the morning or evening?
Morning is the better default. Citicoline's effects on attention and processing speed suggest it can mildly increase alertness. Taking it in the morning avoids potential interference with sleep. No clinical trial has directly compared morning versus evening dosing, so this is a practical recommendation based on the attentional data rather than a tested protocol. If you tolerate it well in the evening, consistency matters more than timing.
Do I need citicoline if my multivitamin already has choline?
Most likely yes, if your goal is brain-specific benefits. Multivitamins typically include 50 to 100 mg of choline bitartrate, well below the studied citicoline doses of 250 to 500 mg. More importantly, choline bitartrate does not provide uridine, the component that drives citicoline's Kennedy pathway activity. A multivitamin covers general choline adequacy but does not replicate the memory, attention, and neuroprotective benefits seen in citicoline trials.
Is alpha-GPC safe?
Alpha-GPC is generally well-tolerated. The most commonly reported side effects are mild: occasional headache, digestive discomfort, and insomnia at higher doses. No serious adverse events were reported in the Jeon 2024 or Kerksick 2024 trials. The primary longer-term safety consideration is the TMAO and cardiovascular pathway covered in the stroke risk question above. This is most relevant for people considering daily use over months or years, particularly those with existing cardiovascular risk factors.
Can I take too much choline from these supplements?
The tolerable upper intake level for choline is 3,500 mg/day for adults (IOM/NAM Dietary Reference Intakes), covering all sources combined (food plus supplements). At standard doses of either compound, you're nowhere near that limit. A 500 mg citicoline dose delivers about 90 mg of choline; a 600 mg alpha-GPC dose delivers about 240 mg. Combined with the 250 to 400 mg most people get from food, you're well within safe range. The more relevant concern for alpha-GPC isn't the choline quantity itself but the TMAO pathway, which operates even at moderate doses. For citicoline, the safety record extends up to 2,000 mg/day in clinical research with no serious adverse events beyond occasional mild GI discomfort.
References
Introduction (2 references)
- US choline intake data: Wallace TC, Fulgoni VL. "Assessment of Total Choline Intakes in the United States." Journal of the American College of Nutrition, vol. 35, no. 2, pp. 108–12, 2016. PubMed
- Health Canada alpha-GPC safety assessment: Health Canada. "Summary of Health Canada's Safety Assessment of L-alpha-Glycerylphosphorylcholine for Use as a Supplemental Ingredient." Canada.ca. Link
Alpha-GPC Compound Profile (1 reference)
- Alpha-GPC metabolic pathways review: Che X, Zhao Y, Xu Z, et al. "Unlocking the Potential of L-alpha-Glycerylphosphorylcholine: From Metabolic Pathways to Therapeutic Applications." Nutrition Reviews, vol. 83, no. 8, pp. 1594–1620, 2025. PubMed
Citicoline Compound Profile (2 references)
- Citicoline plasma levels in humans: Wurtman RJ, Regan M, Ulus I, Yu L. "Effect of Oral CDP-Choline on Plasma Choline and Uridine Levels in Humans." Biochemical Pharmacology, vol. 60, no. 7, pp. 989–992, 2000. PubMed
- Citicoline neuroprotective properties review: Grieb P. "Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues." CNS Drugs, vol. 28, no. 3, pp. 185–193, 2014. PubMed
Pharmacokinetics (5 references)
- Alpha-GPC bioequivalence study: Min MH, Park JH, Hur JH, et al. "Formulation and Bioequivalence Studies of Choline Alfoscerate Tablet Comparing With Soft Gelatin Capsule in Healthy Male Volunteers." Drug Design, Development and Therapy, vol. 13, pp. 1049–1058, 2019. PubMed
- Citicoline pharmacokinetics (1983): Dinsdale JR, Griffiths GK, Rowlands C, et al. "Pharmacokinetics of ¹⁴C CDP-Choline." Arzneimittelforschung, vol. 33, no. 7A, pp. 1066–1070, 1983. PubMed
- Choline quantitation via LC-ESI-MS/MS: Sarkar AK, Ghosh D, Haldar D, et al. "A Rapid LC-ESI-MS/MS Method for the Quantitation of Choline, an Active Metabolite of Citicoline." Journal of Pharmaceutical and Biomedical Analysis, vol. 71, pp. 144–147, 2012. PubMed
- Gpcpd1 and alpha-GPC TMAO pathway: Chen S, Inui S, Aisyah R, et al. "Role of Gpcpd1 in Intestinal Alpha-Glycerophosphocholine Metabolism and Trimethylamine N-Oxide Production." The Journal of Biological Chemistry, vol. 300, no. 12, 107965, 2024. PubMed
- Citicoline pharmacological review (2006 update): Secades JJ, Lorenzo JL. "Citicoline: Pharmacological and Clinical Review, 2006 Update." Methods and Findings in Experimental and Clinical Pharmacology, vol. 28 Suppl B, pp. 1–56, 2006. PubMed
Memory and Cognition (6 references)
- Citicoline memory in older adults RCT: Nakazaki E, Mah E, Sanoshy K, et al. "Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial." Journal of Nutrition, vol. 151, no. 8, pp. 2153–60, 2021. PubMed
- Citicoline vigilance and working memory: Al-Kuraishy HM, Al-Gareeb AI. "Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress." Basic and Clinical Neuroscience, 2020. PubMed
- Citicoline attention in healthy adult women: McGlade E, Locatelli A, Hardy J, et al. "Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women." Food and Nutrition Sciences, vol. 3, no. 6, pp. 769–773, 2012. DOI
- Citicoline motor speed and attention in adolescents: McGlade E, Agoston AM, DiMuzio J, et al. "The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males." Journal of Attention Disorders, vol. 23, no. 2, pp. 121–134, 2019. PubMed
- Alpha-GPC for mild cognitive impairment: Jeon J, Lee SY, Lee S, et al. "Efficacy and Safety of Choline Alphoscerate for Amnestic Mild Cognitive Impairment." BMC Geriatrics, vol. 24, 774, 2024. PubMed
- Citicoline dementia prevention meta-analysis: Bonvicini M, Travaglini S, Lelli D, et al. "Is Citicoline Effective in Preventing and Slowing Down Dementia?" Nutrients, vol. 15, no. 2, 386, 2023. PubMed
Focus and Processing Speed (5 references)
- Alpha-GPC acute cognitive effects in healthy men: Kerksick CM. "Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men." Nutrients, vol. 16, no. 23, 4240, 2024. PubMed
- Citicoline-caffeine attention and concentration: Bruce SE, Werner KB, Preston BF, et al. "Improvements in Concentration, Working Memory and Sustained Attention Following Consumption of a Natural Citicoline-Caffeine Beverage." International Journal of Food Sciences and Nutrition, vol. 65, no. 8, pp. 1003–7, 2014. PubMed
- Citicoline neurocognitive effects (baseline-dependent): Knott V, de la Salle S, Choueiry J, et al. "Neurocognitive Effects of Acute Choline Supplementation in Low, Medium and High Performer Healthy Volunteers." Pharmacology, Biochemistry and Behavior, vol. 131, pp. 119–129, 2015. PubMed
- Citicoline EEG effects in healthy volunteers: Knott V, de la Salle S, Smith D, et al. "Effects of Acute CDP-Choline Treatment on Resting State Brain Oscillations in Healthy Volunteers." Neuroscience Letters, vol. 591, pp. 121–125, 2015. PubMed
- Citicoline sensory gating and executive function: Knott V, de la Salle S, Smith D, et al. "CDP-Choline: Effects of the Procholine Supplement on Sensory Gating and Executive Function in Healthy Volunteers." Journal of Psychopharmacology, vol. 28, no. 12, pp. 1095–1108, 2014. PubMed
Long-Term Neuroprotection (5 references)
- Citicoline stroke efficacy network meta-analysis: Zhao X, Huo X, Meng Y, et al. "The Efficacy of Different Doses of Citicoline in Improving the Prognosis of Patients With Acute Ischemic Stroke." Frontiers in Pharmacology, vol. 16, 1529647, 2025. PubMed
- Alpha-GPC and delayed dementia conversion: Kim HK, Park S, Kim SW, et al. "Association Between L-α Glycerylphosphorylcholine Use and Delayed Dementia Conversion." Journal of Prevention of Alzheimer's Disease, vol. 12, no. 4, 100059, 2025. PubMed
- Uridine dopamine and neurite outgrowth in aged rats: Wang L, Pooler AM, Albrecht MA, Wurtman RJ. "Dietary Uridine-5'-Monophosphate Supplementation Increases Potassium-Evoked Dopamine Release and Promotes Neurite Outgrowth in Aged Rats." Journal of Molecular Neuroscience, vol. 27, no. 1, pp. 137–45, 2005. PubMed
- Citicoline cocaine craving attenuation: Renshaw PF, Daniels S, Lundahl LH, et al. "Short-Term Treatment With Citicoline (CDP-Choline) Attenuates Some Measures of Craving in Cocaine-Dependent Subjects." Psychopharmacology, vol. 142, no. 2, pp. 132–138, 1999. PubMed
- Citicoline appetite and cortico-limbic responses: Killgore WDS, Ross AJ, Kamiya T, et al. "Citicoline Affects Appetite and Cortico-Limbic Responses to Images of High-Calorie Foods." International Journal of Eating Disorders, vol. 43, no. 1, pp. 6–13, 2010. PubMed
Exercise Performance (2 references)
- Alpha-GPC isometric strength in healthy adults: Bellar D, LeBlanc NR, Campbell B. "The Effect of 6 Days of Alpha Glycerylphosphorylcholine on Isometric Strength." Journal of the International Society of Sports Nutrition, vol. 12, 42, 2015. PubMed
- Alpha-GPC physical and psychomotor performance: Marcus L, Soileau J, Judge LW, Bellar D. "Evaluation of the Effects of Two Doses of Alpha Glycerylphosphorylcholine on Physical and Psychomotor Performance." Journal of the International Society of Sports Nutrition, vol. 14, 39, 2017. PubMed
Evidence Strength (2 references)
- Alpha-GPC vs. citicoline meta-analysis: Sagaro GG, Amenta F. "Comparison of the Effects of Choline Alphoscerate and Citicoline in Patients With Dementia Disorders." Frontiers in Neurology, vol. 16, 1649661, 2025. PubMed
- Plasma choline comparison (IM alpha-GPC vs. citicoline): Gatti G, Barzaghi N, Acuto G, et al. "A Comparative Study of Free Plasma Choline Levels Following Intramuscular Administration of L-alpha-Glycerylphosphorylcholine and Citicoline in Normal Volunteers." International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 30, no. 9, pp. 331–5, 1992. PubMed
TMAO and Cardiovascular Safety (7 references)
- Dietary choline supplements and TMAO RCT: Wilcox J, Skye SM, Graham B, et al. "Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function." The American Journal of Medicine, vol. 134, no. 9, pp. 1160–1169.e3, 2021. PubMed
- Phosphatidylcholine vs. choline chloride TMAO: Shirouchi B, Fukuda A, Akasaka T. "Unlike Glycerophosphocholine or Choline Chloride, Dietary Phosphatidylcholine Does Not Increase Plasma Trimethylamine-N-Oxide Levels in Sprague-Dawley Rats." Metabolites, vol. 12, no. 1, 64, 2022. PubMed
- Alpha-GPC stroke risk (12M cohort): Lee G, Choi S, Chang J, et al. "Association of L-alpha Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years." JAMA Network Open, vol. 4, no. 11, e2136008, 2021. PubMed
- TMAO and cardiovascular risk meta-analysis: Heianza Y, Ma W, Manson JE, et al. "Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death." Journal of the American Heart Association, vol. 6, no. 7, e004947, 2017. PubMed
- Citicoline superior form of choline: Synoradzki K, Grieb P. "Citicoline: A Superior Form of Choline?" Nutrients, vol. 11, no. 7, 1569, 2019. PubMed
- Alpha-GPC atherosclerosis promotion (animal): Wang Z, Hazen J, Jia X, et al. "The Nutritional Supplement L-alpha Glycerylphosphorylcholine Promotes Atherosclerosis." International Journal of Molecular Sciences, vol. 22, no. 24, 13477, 2021. PubMed
- TMAO causal direction (bidirectional Mendelian): Jia J, Dou P, Gao M, et al. "Assessment of Causal Direction Between Gut Microbiota-Dependent Metabolites and Cardiometabolic Health: A Bidirectional Mendelian Randomization Analysis." Diabetes, vol. 68, no. 9, pp. 1747–1755, 2019. PubMed
Additional References (4 references)
- Uridine and phosphatide precursors for synapse formation: Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. "Nutritional Modifiers of Aging Brain Function: Use of Uridine and Other Phosphatide Precursors to Increase Formation of Brain Synapses." Nutrition Reviews, vol. 68 Suppl 2, pp. S88–101, 2010. PubMed
- Nutrient combination and synapse formation: Wurtman RJ. "A Nutrient Combination That Can Affect Synapse Formation." Nutrients, vol. 6, no. 4, pp. 1701–10, 2014. PubMed
- Alpha-GPC cognitive dysfunction systematic review and meta-analysis: Sagaro GG, Traini E, Amenta F. "Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis." Journal of Alzheimer's Disease, vol. 92, no. 1, pp. 59–70, 2023. PubMed
- Citicoline neurological disorders systematic review: Jasielski P, Piedel F, Piwek M, et al. "Application of Citicoline in Neurological Disorders: A Systematic Review." Nutrients, vol. 12, no. 10, 3113, 2020. PubMed
This article is for informational purposes only and does not constitute medical advice. Alpha-GPC and citicoline are dietary supplements, not prescription medications. Before starting any new supplement, consult with a healthcare provider, especially if you have existing cardiovascular disease or significant CVD risk factors, are pregnant or breastfeeding, are taking anticoagulant or antiplatelet medications, have kidney disease or impaired renal function, have other chronic health conditions, or are taking prescription medications that may interact with choline supplements.
The information presented reflects current scientific evidence as of March 2026. Research on these compounds is ongoing, and recommendations may evolve as new data emerges. This article does not replace professional medical judgment or diagnostic testing.